Since all business currently is from China, IMDS could be assessing the timing of its listing and/or IPO ( if they are having one ) once things settle down a bit with the us/china trade war.IMO I would think fall would be best timing to start trading.gltu
Maybe not this year.
Nice post Rooster!!
I appreciate you keeping us posted!!!!
IMDS just filed 10 Q for 3Rd quarter ending March 31,2019.
The number of shares outstanding of the issuer’s common stock as of May 9, 2019: 122,523,607 shares of common stock, no par value.
Shares sold recent past for .51 share......On March 22, 2019, the Company issued 392,157 shares of restricted common stock to a non-affiliated accredited investor pursuant to a Subscription Agreement for $200,000. The price per share was approximately $0.51 per share.
IMDS filed Annual Report on April 20,2019 with Florida division of corporations, should appear on SEC soon.We need a bit more patience.gltu
IMDS looks like it will be trading in the near future, cant give you a date.
They have been getting all their ducks in a row.After 4 years we need a little more patience.gltu
QB is better than Pinks and just under QX.You can take a look at Otcmarkets.com and view the different levels.gl.
Thanks for keeping us posted.
And what is the QB category on the OTC?
10 Q out. IMDS looks ready to go... see excerpt as follows;The Company’s next focus, after having obtained CFDA approval in China, is on obtaining marketing clearance of its CTLM® Breast Imaging System through the US FDA. The PMA process for U.S. marketing clearance is expected to take much longer than the Chinese process. Sales in China are expected to commence in the second half of fiscal 2019. No sales in the U.S. are expected in fiscal 2019 or fiscal 2020. The Company has received the CE Mark which would allow it to sell its CTLM® System in the European Union and other countries that recognize the CE Mark; however, the Company does not expect material sales in Europe until it receives U.S. marketing clearance. As of January 27, 2019, Underwriter's Laboratory has not renewed our CE mark as we were not able to provide sufficient evidence in time to meet the deadline. We are working with UL to provide the evidence required to renew the CE Mark. Until the CE Mark is renewed, we will not be able to sell CTLM devices in Europe.
On August 28, 2018, we filed a Form 10 registration statement to register issued and outstanding shares held by our shareholders and to become a fully reporting company under the Securities Exchange Act of 1934 (the “Exchange Act”). The Form 10 was amended in response to SEC comments on October 5, 2018 and November 14, 2018. On February 7, 2019, the SEC confirmed that it has no further comments, on the Form 10. Now that the SEC comment process is completed, we plan on having our stock quoted on the OTCmarkets.com in the QB category. Under the Exchange Act, our registration became effective on October 29, 2018, i.e. 60 days after filing the Form 10.
Also, due to SEC's very limited staffing ( Gov. shutdown), the Security Registration EFFECT date is taking an unusually long time.gl
I understand. Keep in mind that IMDS did not have China FDA clearance.Imo I feel that this will be a new ballgame.
I don't feel there will be any movement in this stock until they start the procedure for an American FDA approval as they did in the old days.
And we all know what happened after that.
Just my opinion tho . . .
Totally new ball game now.IMDS is now legit company. Gltu.
I can recall that back in those days, 2014, the Grables were running the company, her and her daughter, whose name escapes me.
IMDS CEO info Ms. Chunming Zhang has been Chief Executive Officer of Imaging Diagnostic Systems Inc. since September 2014. Ms. Zhang has been Vice President of Sanya Wanbo (Viable) Investments, Ltd. Co, since December 2013. Ms. Zhang previously held a marketing position in China for a number of years with Dr ger Medical GmbH, with headquarters in L beck, Germany. She has been a Director at Imaging Diagnostic Systems Inc. since August 4, 2014. She has been a Director of Sanya Wanbo (Viable) Investments, Ltd. Co, since December 2013.
IMDS POTENTIAL MARKET & REVENUE.
Based on 667 m Chinese females of which approx 290+ m would be over age 40, versus USA 164 m female with 81 m over age 40.
Approx 65 % of USA received mammograms = 52 m tests.
China's mammogram ratio will be dramatically lower,lets assume 20 % of over age 40 = 58 m tests.
Therefore the Chinese market should be at least equal to the US market.
Next, how many mammograms can one IMDS CTLM perform in a year? No idea, but lets assume the maximum scenario; 15 minutes per test, 4 tests per hour x 18 hours a day x 6 days per week x 52 weeks = 22,500 tests annually.
45 CTML machines would be required per 1 m tests.Assume IMDS is able to secure 10 % of the Chinese market =5.8 m tests =260 CTML machines.GLTA.
IMDS could become multi million dollar company now that they approved for manufacturing and sale in CHINA.
Based on $ 75,000 per unit sold coupled with China's population of 1.4 Billion people, the potential is staggering.$1.00 plus a share is quite possible.
We could see IMDS receiving "EFFECT" for relisting any day now, maybe around the end of this week.
Anyway, attempting to spur some excitement.I am totally hyped.glta.
Fabulous NEWS.IMDS approved China FDA.On November 17, 2018, Imaging Diagnostic Systems, Inc. ("IDSI" or “we” or “our”) received notice from Xi'an IDI Laser Imaging Co., Ltd.("Xi'an") our licensee (as described below) that the CTLM® Breast Imaging System had been approved by the Shaanxi Drug Administration on November 16, 2018 and would be effective until November 15, 2023. The Peoples Republic of China issued a Registration Certificate for Medical Device, Certificate No.: Shaanxi 20182060079. This approval allows Xi'an to manufacture, sell and distribute the CTLM® in China.
In June 2017, we entered into a Technology Licensing Agreement (the “Xi’an Agreement”) with Xi’an, of Xi’an, Shaanxi Province, China. Xi’an is an affiliate of Viable International Investments, LLC which owns a majority interest of IDSI. Under the terms of the Xi’an Agreement, Xi’an has the exclusive right to manufacture the CTLM® in China and sell the CTLM® in China, Hong Kong, Macau and Taiwan. Xi’an is required to pay to IDSI on a quarterly basis a royalty of 25% of the gross revenues from the sale of the CTLM® and related parts and accessories. We expect Xi’an to sell the CTLM® in China for approximately $300,000 per unit.
it sure would be nice
By my calculations there are 120,643,616 IMDS shares outstanding after the 1000 to 1 reverse split.Market cap at.20 share would be just over 24 million.Approval in China ?$$ ( population of approx.1.4 billion), FDA approval ?$$.This might be one of the highest potential stocks yet in the Medical Device field.Time will tell.GLTA.
Just reading thru the IMDS registration again.This company could yield amazing return if there plans succeed i.e. they recieve China approval.GLTA
IDSI is expecting China FDA (“CFDA”) marketing clearance by the end of 2018, and we will next focus on U.S. FDA marketing clearance. After our December 2015 informational meeting with the FDA, we drafted a revised clinical investigation plan for purposes of the PMA process (“CIP”); however, we have not yet submitted the CIP to the FDA as we have been focusing since 2016 on our initial goal of obtaining CFDA marketing clearance and launching operations in China. We are evaluating our PMA pathway and strategy as additional data and experience from our current trials and the CFDA approval process become available. All of the data and trials we have assembled and conducted to date are for internal evaluation purposes and not for submission to the FDA. Once we have developed a clear PMA strategy in conjunction with our FDA consultants, which we expect to have by mid-2019, all of our clinical trials going forward will be designed to meet the FDA’s requirements for the PMA process.
You are welcome.
Since our stock reverse split (1000 to 1 ) coupled with the Security registration, IMO we should be trading ( possible symbol change ) in the next few months.
The key factor will be if they receive China approval, end of 2018 December?
Looks like IMDS might actually rise from the dead.GLTU
Thanks for keeping us posted on this company.
Does this mean that our stock that we have been holding for years, the common, will become tradeable again?
Or will they be issuing new common stock for sale to the public.
AMENDED 10-12G/A Registration of Securities out.
Looks like the current management are professional.
Some shares sold for .20 to .51 GLTA.
During the fiscal year ended June 30, 2018, IDSI sold 2,941,176 shares of common stock to four non-affiliated accredited investors for gross proceeds of $1,500,000 ($0.51 per share).
Could be a while yet.Keep watching for SEDAR postings.Here is the link;
IDSI filed Articles of Amendment with the Florida Secretary of State for a 1 for a 1000 reverse split of IDSI’s common stock on July 12, 2018 (the “Reverse Split”). Also stipulated in the amended articles was a reduction of authorized shares of its common stock from 40,000,000,000 to 500,000,000 which became effective on July 27, 2018 (the “Share Reduction”).
After the Share Reduction, IDSI’s authorized capital stock consists of 500 million shares of common stock, no par value, and 2 million shares of preferred stock. As of August 20, 2018, following the Reverse Split and Viable’s August 7, 2018, conversion of all of its remaining shares of Series M preferred stock, there are 120,641,330 shares of IDSI common stock issued and outstanding and 20 shares of Series L preferred stock issued and outstanding
Cool - $38 to go from 1MM shares to 1,000.
Maybe it does start trading soon.. i hope so.
April 23, 2018, 12:38 AM CDT Royal Philips NV Chief Executive Officer Frans van Houten said the Dutch manufacturer of medical equipment remains on the hunt for companies to buy as it hones focus on the health-care sector.
“We are interested to do bolt-on acquisitions,” he said in an interview on Monday with Bloomberg TV after publishing quarterly earnings. “Deals done last year were bolt-on, not transformational from a size point of view, but very important nuggets.”
Frans van HoutenPhotographer: Jasper Juinen/Bloomberg
The company based in Amsterdam reported 10 percent growth in comparable order intake, reflecting a series of multi year contracts to provide imaging services to hospitals including in the U.K. and Canada. It reiterated targets for the coming years as demand for health equipment like ultrasounds grows. The shares jumped as much as 4.2 percent, the most in nine months.
Philips has pledged to increase sales and improve profit margins after refocusing its business on health-care equipment and services while exiting from the manufacture of products like light bulbs, TVs and CDs. The Dutch company competes with General Electric Co. and Siemens AG in selling X-ray and scanning machines and last year, it spent about 2.3 billion euros ($2.8 billion) on acquisitions, including buying a U.S. maker of devices to treat cardiac diseases.
“Doing a transformation of a company is not easy,” the CEO said in the interview, citing Philips’s move from being a more diversified manufacturer to a “focused” health technology company that is now gaining market share.
On a call with reporters, he said the company’s higher order growth will pave the way for “structurally higher growth for Philips overall.”
Philips’s diagnostics and treatment business, which makes imaging machines, reported the fastest growth among the company’s divisions with comparable orders rising 15 percent while sales increased 9 percent.
Received mine today.At least it wont look so bad.My 38 m goes to 38,000.Wonder if this will ever trade?
I doubt it.
I'm sure we will be hearing from Stockmasterflash and Javonscanner and a few others on this subject here in a few moments.
Wonder if we'll be trading again soon.
Yes, I received an email from E*Trade and Ameritrade.